Results of the 2nd price ceiling reevals to be released soon

NHIS plans to hold a preliminary briefing session

Will start negotiations in mid-December…plans to conduct preliminary discussions with companies due to the short deadline

The National Health Insurance Service plans to hold a preliminary briefing session before starting its main negotiations for the 2nd drug price ceiling re-evaluations.

 

The authorities decided upon this measure to inform companies in advance about the documents that would need to be submitted for negotiations due to the tight 10-day negotiation deadlines.

 

According to industry sources on the 17th, the NHIS will be conducting an online briefing session for the 2nd drug price ceiling re-evaluation negotiations on the 23rd.

 

The NHIS said, “Due to our tight schedule, including the Drug Reimbursement Evaluation Committee meeting expected in early December, we expect the negotiation period for the companies to be limited to 10 days or so.

 

Although the drugs subject to negotiations have not been finalized yet, the briefing session will be held for all pharmaceutical companies to minimize the burden work burden on the NHIS and companies.” Also, the NHIS asked for the companies to prepare and submit their negotiation documents in advance to complete the negotiations in the set period.

 

Also, for the convenience of negotiation administrations and simplification of documents, the process will be completely converted and conducted electronically.

 

Currently, 6,700 items are subject to the 2nd insurance price ceiling reevaluations.

 

These are some of the oral and sterile preparations ETCs the Ministry of Food and Drug Safety included as in need of bioequivalence verifications.

 

Following re-evaluations, the prices of the subject drugs will be reduced according to the standard requirements.

 

The requirements are ▲ completion of in-house bioequivalence tests or clinical trials ▲ using raw drugs registered with the MFDS when manufacturing finished drugs.

 

The price of those that only meet one of the requirements is adjusted to 85%, and those that meet none are adjusted to 72.25% of the previous price HIRA has been conducting reevaluations after receiving data from pharmaceutical companies until July this year.

 

The NHIS will start the main negotiations in mid-December after the results are deliberated by DREC at its meeting on December 7th.

 

Then the results will be reported to the Health Insurance Policy Deliberative Committee and pricing adjustments applied from January next year.

 

Meanwhile, the price ceiling of 7,675 items had been adjusted in September through the 1st drug price ceiling re-evaluation negotiations.